Mastermind Session: Balancing Science & Stakeholder Expectations: Navigating Non-Animal Testing Roadmaps in Tumour Model Strategy
- How will the new roadmaps encouraging non-animal tests from the FDA, and the UK affect your tumour model selection?
- How do you manage investor and senior-level expectations following these changes?
- Will investors continue to ask for in vivo/NHP data, or will their requirements change?